90% Reduction in COVID-19 Virus Infectivity Reported Through Independent University Research Study
NEW YORK, NY, April 26, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that Immunitor, its Licensing partner, continues to receive favorable reports from people in Asian and African countries using the Immunitor HAP-V+ Immune Supplement in cases of respiratory infections.
Originally developed some 10 years ago as a patented oral pill vaccine to support strong immunity, as this is the obvious natural defense to catching colds and/or viral infections, HAP-V+ is today increasingly being used in countries where it is currently available in cases of COVID-19.
In some of these countries where both supplement and/or treatment options are very limited, people with COVID-19 have been resorting to the Immunitor supplement, many later advising that within days of taking HAP-V+, they began to feel better. This supports the extensive anecdotal use reports of people feeling better within as little as 24 hours when taking HAP-V+ on the first evidence of cold or flu.
As reported earlier this year, preliminary tests conducted by a leading Asian university research institute on the Immunitor HAP-V+ Supplement have shown safety and a 90% reduction on SARS-CoV-2 virus infectivity in mammalian cells following exposure to HAP-V+. This laboratory testing highlights HAP-V+ methodology and its potential to inactivate and/or prevent viral infection, and its oral mucosal administration advantage.
Whilst all supplement use feedback and early laboratory results continue to be encouraging, to progress regulatory approval for HAP-V+ as a treatment for COVID-19, influenza, and other respiratory conditions, will still require substantial validation through clinical trials. To progress efficacy studies and regulatory approvals, Key Capital and Immunitor have established an international project management team, clinicians, infectious disease scientists, and advisors from many countries that are recognized experts in viral and infectious disease science. Final clinical strategy and development plans are now progressing through this international cooperation and are expected to be proceeding in the second half of 2021.
24/7 Immune BODY – For Strong Natural Immunity
In the interim, MaxCellLife.com, Key Capital’s marketing arm will sell HAP-V+ as 24/7Immune BODY as a dietary supplement to support and promote natural immunity as from early May 2021.
MacCellLife MIND – For Natural Anxiety and Stress Support
Anxiety, stress, depression are all significant social issues today. Moreover, the impacts of the COVID-19 pandemic are additionally contributing to the global mental health burden, both directly and indirectly. As recently reported by CNN, a study of over 200,000 COVID-19 patients by Oxford University, published in The Lancet has revealed that in people treated for COVID-19 some 17% were suffering from anxiety, and 14% from mood disorders.
MIND by MaxCellLife is a unique, world-first supplement with the potential to optimize the gut-brain connection through natural support for people with anxiety or stress related issues. Wellness, from the inside out. See: https://MaxCellLife.com/Mind
MaxCellLife MIND may be an ideal natural support for people with day-to-day anxiety or stress issues, without any risk of product addiction and/or adverse withdrawal symptoms.
For all supplement detail, purchases or inquiries see: https://MaxCellLife.com